Vincristine sulfate

Name: Vincristine sulfate
Brand: Selleck Chemicals
SKU: S1241
Rating: 5 (35 reviews)

For research use only. Not for use in humans.

Catalog No.S1241 Synonyms: Leurocristine

35 publications

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Selleck's Vincristine sulfate has been cited by 35 publications

Cancer Discov, 2019, 9(2):230-247

PubMed: 30373918 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

Cancer Lett, 2020, 469:111-123

PubMed: 31639426 ( click the link to review the publication )

Cancer Res, 2019, 79(20):5382-5393

PubMed: 31405846 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Rep, 2019, 26(6):1544-1556

PubMed: 30726737 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 31742555 ( click the link to review the publication )

J Lipid Res, 2019, 60(6):1078-1086

PubMed: 30962310 ( click the link to review the publication )

Biochem Pharmacol, 2019, 170:113642

PubMed: 31541631 ( click the link to review the publication )

Oncotarget, 2019, 10(60):6403-6417

PubMed: 31741706 ( click the link to review the publication )

J Exp Med, 2018, 215(8):2137-2155

PubMed: 30045945 ( click the link to review the publication )

J Exp Med, 2018, 215(12):3094-3114

PubMed: 30404791 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1965

PubMed: 30530705 ( click the link to review the publication )

Leukemia, 2018, 32(3):616-625

PubMed: 28904384 ( click the link to review the publication )

Chemosphere, 2018, 210:467-475

PubMed: 30025364 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9273-9284

PubMed: 29507689 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )
Drugs R D, 2017, 17(2):287-296

PubMed: 28299646 ( click the link to review the publication )

Cell Death & Disease, 2017, 10.1038/cddis.2017.454

PubMed: ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1335-1351

PubMed: 28496304 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2017, 18(1):63

PubMed: 28877739 ( click the link to review the publication )

ACS Cent Sci, 2016, 2(8):545-59

PubMed: 27610416 ( click the link to review the publication )

Lipids Health Dis, 2016, 15:152

PubMed: 27613245 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(10):909-919

PubMed: 27358112 ( click the link to review the publication )

Cell Rep, 2015, 13(11):2353-2361

PubMed: 26686626 ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 350(3):646-56

PubMed: 24993360 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):10736-49

PubMed: 23109819 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Targets

Microtubules ^[1]
(Cell-free assay)

32 μM

In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with K_i of 85 nM. ^[1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. ^[2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. ^[4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HepG2.2.15	M165OWNmdGxiVnnhZoltcXS7IFHzd4F6	MnH2NE0xNjVizszN	Mo\pNlQhcA>?		MnvT[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MXuyOVY3Ozd4OR?=
HepG2-HBV1.1	MUHBdI9xfG:\|aYOgRZN{[Xl?	NYDQOpk3OC1yLkWg{txO	M3Kzc\|I1KGh?		MnzCbY5lfWOnczDhdI9xfG:\|aYOg[I9{\SCmZYDlcoRmdnSueR?=	M1HKXFI2PjZ\|N{[5
HepG2.2.15	M1e2c2Z2dmO2aX;uJGF{e2G7	NWT6O2hxOC5zIN88US=>	NULve2VyOjRiaB?=		MnTKdJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO\|aX;u	MUOyOVY3Ozd4OR?=
HepG2-HBV1.1	MXLGeY5kfGmxbjDBd5NigQ>?	NEKzbG4xNjFizszN	M2rPfFI1KGh?		NUnhb\|dFeHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v	NXfnTmpIOjV4NkO3Olk>
HepG2-HBV1.1	NIG4Z2tHfW6ldHnvckBCe3OjeR?=	NH7DOHUxNjFizszN	Mm[wOFghcA>?		MXPwdo9ud3SnczDj[YxtKGW6Y4LleIlwdiCxZjDo[ZBifGm2aYOgRkB3cXK3czDueYNt\W:lYYDzbYR{KGmwc4TlZYQhd2ZiaHXwZZRqfGm\|IFKgeolzfXNiRHHu[UBx[XK2aXPs[ZM>	MVyyOVY3Ozd4OR?=
HepG2-HBV1.1	M2\GSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVGwMlEh\|ryP	M{\jPVEuPSCm		M2rxNYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm=	M2fvbVI2PjZ\|N{[5
HepG2-HBV1.1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\lNE4yKM7:TR?=	MonvNU02KGR?		NHvyd5pqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckB1cW2nIHTldIVv\GWwdHz5	NYnkU25NOjV4NkO3Olk>
HepG2-HBV1.1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\CUlAvOSEQvF2=	NIXrSVcyOi15MjDo		M3rzbYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=>	M4LIUVI2PjZ\|N{[5
HepG2-HBV1.1	NHTJNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NID5SJUxNjFizszN	MWixNk04OiCq		NGrheHBqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U>	M1f2XlI2PjZ\|N{[5
Raji	MmnhSpVv[3Srb36gRZN{[Xl?	Mkm0NE42yqEQvF2=	NIHWWGs4OiCq		MoKxZYJwdGm\|aHXzJIF2fG:yaHHnfeKh	NFjtR2UzPTR2NkO3Oy=>
SK-MEL-28	Mo\ESpVv[3Srb36gRZN{[Xl?	NF3RdZc{OCCwTR?=	M2nJUFYhcA>?		M3;Tb4lv\HWlZYOgS\|LjiJOPIHPlcIwu[3mlbHWgZZJz\XO2	NWD3WXpxOjV\|MUOwNVA>
H157	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHU[m9wUUN3ME2xMlA{KMLzIECuNFQhdWm3Ml2=	MlLNNlUzPTd7MUG=
Jurkat	NYfWR2tsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX[xMVMhdk1?	MW[0POKhcA>?	M4H4ZmROW09?	NYnvNoJS\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>?	MUWyOVE2PjF2Nh?=
CEM	MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XueVEuOyCwTR?=	M2W0N\|Q5yqCq	M1zKV2ROW09?	M3jCOoRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk>	NVnRTJhSOjVzNU[xOFY>
P12	NUPXcoU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mki2NU0{KG6P	NHPh[5o1QMLiaB?=	MWHEUXNQ	MVLk[YNz\WG\|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5	NWDVXVEyOjVzNU[xOFY>
KB	NFrTfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWizOnpRUUN3ME2wMlAxPDliwsGgNE4xODBzIN88US=>	MXmyOVA2QDV{Nh?=
KBv200 (ABCB1)	M2TrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{ntUGlEPTB;MD6zOFYzKMLzIECuNFA3PiEQvF2=	NHjDeWQzPTB3OEWyOi=>
SUDHL6	M1[2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;rR\|HjiIoQvF2=	MWi0PE84OiCq		NUnGXoE1cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>?	NFPwPWozPDl4MU[wOC=>
SUDHL6	M4TiOmZ2dmO2aX;uJGF{e2G7	MVSx5qCK\|ryP	NH61eYE4OiCq		M4S0TIlv\HWlZYOgd4lodmmoaXPhcpQh[XCxcITveIlkKG2xcoDoc4xw\3liY3jhcodmeyClb4Ty[ZN1\WRid3n0bEBDS0xzMVGgd4lTVkF?	MmjmNlQ6PjF4MES=
HCT-116	MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MomxS2k2OD13IH7N	MXWyOFkzPzh3Nx?=
SKNBe2C	NXfsUphjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlT1TWM2OD1\|Mj64xtE1NjBibl2=	NH7EdZczPDl{MUmyNC=>
IGNR91	M3vZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPsWWtKSzVyPUK0MlPDuTFwNzDuUS=>	M{PaRlI1QTJzOUKw
SKNAS	NXrrXo9IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTFwNdMxNE4zKG6P	NEK5dHIzPDl{MUmyNC=>
LAN1	NU\KZZJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYroWmhNUUN3ME2yMlPDuTBwMjDuUS=>	MUOyOFkzOTl{MB?=
SHSY5Y	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRThwMtMxNE43KG6P	NVjLS5hlOjR7MkG5NlA>
A549-WT	M2DvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;HTWM2OD1zOT60N\|chyrFiMD61PVQhKG6P	MnPqNlQ5PTh6Mke=
A549-R	NI\De2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHL[JE6UUN3ME2xNk4yPzhiwsGgNE4{OzNiIH7N	MVSyOFg2QDh{Nx?=
MCF-7-WT	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnneZF6UUN3ME2xO{44PTJiwsGgNE4zOThiIH7N	M4TWT\|I1QDV6OEK3
MCF-7-R	NFfmbJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\2TWM2OD13LkWzPUDDuSByLkG0OEAhdk1?	MonjNlQ5PTh6Mke=
A549-R	MVvDfZRwfG:6aXPpeJkhSXO\|YYm=				M{i5ZmlEPTB;MUKuNVc5KMLzIECuN\|M{KG6P	NEPnfWMzPDh3OEiyOy=>
MCF-7-R	MVXDfZRwfG:6aXPpeJkhSXO\|YYm=				MVvJR\|UxRTVwNUO5JOKyKDBwMUS0JI5O	MV[yOFg2QDh{Nx?=
SW620	NH3xSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TXW2lEPTB;Nz64NEDDuSByLkC4JI5O	NIe5c2UzPDd{NkezPS=>
SW620/AD300	NGKxZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTlyOT62NEDDuSB6LkmxJI5O	MlzzNlQ4OjZ5M{m=
HEK293/pcDNA3.1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlq5TWM2OD1zLkS1JOKyKDBwMkCgcm0>	NI\GZXMzPDd{NkezPS=>
HEK293/ABCC1	Ml\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTF7LkK5JOKyKDJwMEigcm0>	MkDWNlQ4OjZ5M{m=
TCC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHq0eVAzPCCq		M2S3R2lEPTB;N{Cgcm0>	M2XtclI1PzF4OUS0
TCC	NIHuUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVK0PEBp		MUHJR\|UxRTVyIH7N	NXj0bppZOjR5MU[5OFQ>
HepG2/ADM	MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTJwN{i2N:KyOC5{M{exJO69VQ>?	MX:yOFcxPDV3Nh?=
HepG2	Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LIcGlEPTB;MD6wNVE2yrFyLkCwNVch\|ryP	NIrYe3kzPDdyNEW1Oi=>
MCF-7/ADR	M{HRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFy3N\|hKSzVyPUSuOFgzPsLzMD6yNFcxKM7:TR?=	M2DTWFI1PzB2NUW2
MCF-7	M1vFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nnfWlEPTB;MD6wNVU6yrFyLkCwOlIh\|ryP	MmfKNlQ4ODR3NU[=
A-172	NF;wW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn[xNE4yyqEQvF2=	NX\FPHNZOjRxN{KgbC=>		MWXpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5	M2\FNFI1PTNyMkO1
U-251MG	NXXhRVFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHsNE4yyqEQvF2=	NYHCeVNWOjRxN{KgbC=>		MYHpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5	NHj4blAzPDV\|MEKzOS=>
DLD-1	MYLGeY5kfGmxbjDBd5NigQ>?	NF\6cpAyODBibl2=	Mnr0OFghcA>?		NUntZpVIeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi	NF;qfIYzPDRyM{S1Ny=>
CCD18Co	M37zbGZ2dmO2aX;uJGF{e2G7	M{SzcFExOCCwTR?=	NUXz[WdHPDhiaB?=		Moi2dJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh	MUGyOFQxOzR3Mx?=
DLD-1	M4XYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPzdI4xNTFyMECgcm0>	M{X2O\|Q5KGh?		NILRUJJqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6	NXLxR4FnOjR2MEO0OVM>
CCD18Co	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXiwMVExODBibl2=	MV:0PEBp		M3joSIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	NFi2eXMzPDRyM{S1Ny=>
HepG2	NHizVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlWzNlQhcA>?		MUHJR\|UxRTV{LkZihKnPxE1?	MWKyOFM1OTZ6OB?=
HEK293/pcDNA3.1	MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTBwMEC0xtExNjByMEOg{txO	MWeyOFI5PDd6Mx?=
HEK293/MRP1	MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTBwMEW1xtExNjBzMkCg{txO	NXz2cJRzOjR{OES3PFM>
Ramos	M3XLSmFxd3C2b4Ppd{BCe3OjeR?=	MVuy5qCK\|ryP	Ml7XOFghcA>?		NVLPO2l5cW6mdXPld{A{PC54JdMxNU46OiViYYDvdJRwe2m\|	MkDYNlQzPTZ2OUG=
NCI-H1299/pcDNA3	M37RemNmdGxiVnnhZoltcXS7IFHzd4F6	MofvNE0zOCCwTR?=	NF72TWI6PiCq		MUXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	M1P1W\|I1OTd5MEGy
H1299/ICAM-3	NVroUmFtS2WubDDWbYFjcWyrdImgRZN{[Xl?	NYezfodLOC1{MDDuUS=>	NH\IdG86PiCq		NUTIN5hYcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	Mn7mNlQyPzdyMUK=
NCI-H1299/pcDNA3	MXvGeY5kfGmxbjDBd5NigQ>?	MonVNU82NzFyL{KwxsBvVQ>?	M4XwXFk3KGh?		M2jERYlv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA>	M{XBcFI1OTd5MEGy
H1299/ICAM-3	M3rFT2Z2dmO2aX;uJGF{e2G7	Mn\ZNU82NzFyL{KwxsBvVQ>?	MmPyPVYhcA>?		NXvRW\|htcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1\|LDC4MEA6NCCjbnSgVGFTWA>?	NUjucFMxOjRzN{ewNVI>
W1	NF74SmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HHeWlEPTB;MD6wNFMzKM7:TR?=	Mlm1NlQyPDBzN{[=
W1VR	MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{mwSGlEPTB;MD6wOVYh\|ryP	MVuyOFE1ODF5Nh?=
K562	NXrGfIpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTBwMEOyJOKyKDBwMECxJEDPxE1?	MVSyOFE{PTl\|Nx?=
K562/ADR	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7Q[2JKSzVyPUOuNlYyKMLzIECuOFEzKM7:TR?=	M3jldVI1OTN3OUO3
K562	MVnBdI9xfG:\|aYOgRZN{[Xl?	MYqwMlMh\|ryP	M3nkc\|I1KGh?		NGjQZYZqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7	M3i3eVI1OTN3OUO3
K562/ADR	NGrmW5hCeG:ydH;zbZMhSXO\|YYm=	NH7LZoM{KM7:TR?=	MUCyOEBp		MWPpcoR2[2W\|IHHwc5B1d3Orcx?=	NVvoNXNIOjRzM{W5N\|c>
A549	Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYS1WIdxUUN3ME2wMlExKMLzIECuNFMh\|ryP	NFTOTIwzOzl5MUC3OS=>
K562	NX3sTI5WS2WubDDWbYFjcWyrdImgRZN{[Xl?	NHXzNGg{Njd34pETOlDDqG6P	M4DpRVczyqCqwrC=		NHHKXJZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	MXiyN\|g4PzJ{Mx?=
lucena	NGLJfZJE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M1jkeFMvPzYkgKO2NOKhdk1?	Mn3pO\|LDqGkEoB?=		MYnuc{Bm\m[nY4S=	NFnCcFEzOzh5N{KyNy=>
FEPS	MlvMR4VtdCCYaXHibYxqfHliQYPzZZk>	M{fDfFMvPzYkgKO2NOKhdk1?	MUG3NuKhcMLi		MYfuc{Bm\m[nY4S=	NF\aTWwzOzh5N{KyNy=>
A2780	M{HHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TwRWlEPTB;Mz61JI1O	MmHxNlM5Ojl{MEO=
ACHN	MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRDBwMTDtUS=>	MkjNNlM5Ojl{MEO=
U-937	Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2r0bGlEPTB:M{Sgcm0>	NH7ueGIzOzh{OUKwNy=>
Jurkat	M4PBUmFxd3C2b4Ppd{BCe3OjeR?=	NVvVZ4h4PcLizsznM41tyqB?	M{\4XFI1KGh?		M4LX[olv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl?	NHjDdm4zOzhzMESwPS=>
Jurkat	NV3PXohoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfKbVk2yqEQvHevcYzDqA>?	Mk\INlQhcA>?		NIS3PINienKnc4SgTpVzc2G2IHPlcIx{KGmwIFeyM20heGijc3W=	MV:yN\|gyODRyOR?=
Hep-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTBwMEVCtVAvODFizszN	MmjSNlM4QDB2MkS=
Hep-2/v	M17lZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXoTWM2OD1zLklCtVAvOjBizszN	MUmyN\|c5ODR{NB?=
SGC-7901	Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjBSHYxNTFyIN88[{9udA>?	NIezU5IzPC92OD:3NkBp		NEG0[FFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	NYTjRZBmOjN5NEO1O\|I>
SGC-7901/VCR	MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4W0dFAuOTBizsznM41t	MYGyOE81QC95MjDo		Mm\ibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	MljUNlM4PDN3N{K=
SGC-7901	NEDqZ3dCeG:ydH;zbZMhSXO\|YYm=				Ml\XbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgQ>?	MWOyN\|c1OzV5Mh?=
SGC-7901/VCR	M1LLdGFxd3C2b4Ppd{BCe3OjeR?=				MlHSbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgQ>?	M1:0cFI{PzR\|NUey
KB-3-1	Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIX4O5hKSzVyPUGuOlYhyrFiMD6xOlIh\|ryP	M4fo[VI{Pjd\|NES1
KB-C2	M{DyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XvZ2lEPTB;MkCyMlU3KMLzIESyMlQ5OSEQvF2=	MnLtNlM3PzN2NEW=
KB-3-1	Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PkeGlEPTB;MT6yOkDDuSByLkCyO{DPxE1?	MojINlM3PzN2NEW=
KB-V1	NF21RndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{[0[mlEPTB;MkC4Mlg2KMLzIEKwMlQh\|ryP	NIewWXMzOzZ5M{S0OS=>
HEK293/pcDNA3.1	NH;GZ\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrVTWM2OD1{ND6xJOKyKDBwMkC0JO69VQ>?	MVWyN\|Y4OzR2NR?=
HEK293/ABCB1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ru[mlEPTB;M{WxNk45KMLzIEO3PE4{QTFizszN	MX6yN\|Y4OzR2NR?=
A549/EGFP	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLvZmF[OC5yMT2xNFAxKM7:TR?=			Mlr6TWM2OD16Nj63JOKyKDJ7LkGg{txO	M1v4dlI{PjN2Mkiy
A549/Slug	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3T[FAxNjBzLUGwNFAh\|ryP			NIDUcXNKSzVyPUmuO{DDuSB\|LkGg{txO	NXjwe2JvOjN4M{SyPFI>
JFCR39	Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjrenpWOSEEtV2=	MXyyOEBp	M{foeWROW09?	MmLVcYFzc2WmbImgbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiR{KvUUBxcGG\|ZTDj[Yxtew>?	NYDMUYVkOjN3OUiyO\|Y>
A549	MUHGeY5kfGmxbjDBd5NigQ>?	NGXBVlIyODBibl2=	M3y0RVE3KGh?	MXzEUXNQ	MVHs[YFleyC2bzDhJIxwe3Nib3[gcYlkem:2dXL1cIV{	MWWyN\|U6QDJ5Nh?=
SGC7901	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTFwMkdihKnDueLCiUCuNVEh\|rypL33s	NV;XXXdSOjN3NkS0PFI>
SGC7901/LV-NC	NE\NZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFW4ZZBKSzVyPUGuO\|fjiIoEsfMAjVAvOTZizsznM41t	NXvzWXNrOjN3NkS0PFI>
SGC7901/LV-SGO1	NETOVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnRTWM2OD12LkO25qCKyrIkgJmwMlM4KM7:Zz;tcC=>	MnyxNlM2PjR2OEK=
SGC7901/VCR	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nMR2lEPTN;MkCuOVPjiIoEsfMAjVEvQTZizsznM41t	MXqyN\|U3PDR6Mh?=
SGC7901/VCR-NC	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rFfWlEPTB;MUmuPFbjiIoEsfMAjVIvODFizsznM41t	MYKyN\|U3PDR6Mh?=
SGC7901/VCR-si-SGO1	NWruNJlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjmTI46UUN3ME22MlE56oDLwsJihKkyNjB\|IN88[{9udA>?	M3\qe\|I{PTZ2NEiy
SGC7901/ADR	MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVK5coR4UUN3ME23Mlg26oDLwsJihKkxNjZ2IN88[{9udA>?	NXu0U2FpOjN3NkS0PFI>
SGC7901/ADR-NC	NFfRdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGi3No9KSzVyPUiuPVPjiIoEsfMAjVAvPjhizsznM41t	MV[yN\|U3PDR6Mh?=
SGC7901/ADR-si-SGO1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2qyfmlEPTB;Mz60OwKBkcLz4pEJNE4zQSEQvHevcYw>	NUfiUJp5OjN3NkS0PFI>
SH-SY5Y	M3TpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\rO\|AvODBzLUGwJO69VQ>?	MoPONlQhcA>?		NGTI[YJKSzVyPUCuNVE{yrFyLkCxNkDPxE1?	NF3vcFEzOzF{OUC2OS=>
SH-SY5Y	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4C2VFAvODBzLUGwJO69VQ>?	MkH0OFghcA>?		MmTUTWM2OD1yLkC3POKyOC5yMEmg{txO	MlXtNlMyOjlyNkW=
SH-SY5Y	NHjpZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3W3O\|AvODBzLUGwJO69VQ>?	NYHWcnZqPzJiaB?=		MkXuTWM2OD1yLkC1NeKyOC5yMEig{txO	NGX1XYEzOzF{OUC2OS=>
SH-SY5Y	MYDBdI9xfG:\|aYOgRZN{[Xl?	Ml3nNE4yKM7:TR?=	M3jwWlAuOjRiaB?=		MmDxbY5lfWOnczDhdI9xfG:\|aYOgc4YhW0hvU2m1XUBk\WyuczDmc4xtd3erbnegZ4VtdCCleXPs[UBienKnc4SgZZQhfGinIFeyM20heGijc3W=	MWGyN\|EzQTB4NR?=
SH-SY5Y	M1PEUmFxd3C2b4Ppd{BCe3OjeR?=	MY[wMlEh\|ryP	MorGNE0zPCCq		MV;pcoR2[2W\|IH3peI91cWNiYYLy[ZN1yqB?	NEmxZlEzOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; PubMed: 26156322 J Hematol Oncol MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine	26156322
Growth inhibition assay	Cell viability ; PubMed: 26156322 J Hematol Oncol MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively. Cell viability was measured by MTT assay.	26156322

In vivo

Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. ^[6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . ^[7]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: B16 melanoma cell
Concentrations: 10 nM
Incubation Time: 3 days
Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 10⁴ cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO₂ and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
(Only for Reference)

Animal Research:^[6]

- Collapse

Animal Models: Human rhabdomyosarcoma xenografts Rh12
Formulation: Water solutioin
Dosages: 3 mg/kg
Administration: A single i.p. administration
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (108.33 mM)
	Water	60 mg/mL (65.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vincristine sulfate SDF

Molecular Weight	923.04
Formula	C₄₆H₅₈N₄O₁₄S
CAS No.	2068-78-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	Leurocristine
Smiles	CCC1(O)CC2CN(CCC3=C([NH]C4=C3C=CC=C4)C(C2)(C(=O)OC)C5=CC6=C(C=C5OC)N(C=O)C7C(O)(C(OC(C)=O)C8(CC)C=CCN9CCC67C89)C(=O)OC)C1.O[S](O)(=O)=O

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03981510	Recruiting	Diagnostic Test: 3D-Transit	Constipation\|Childhood Acute Lymphoblastic Leukemia\|Neurofibromatosis 1\|Chronic Constipation With Overflow	University of Aarhus	June 2019	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?
Answer:
According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Paclitaxel

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Docetaxel

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vincristine sulfate